Phase 3 Trial: Bleximenib Menin-MLL Inhibitor for Acute Myeloid Leukemia

This Phase 3 randomized, double-blind study evaluates whether adding investigational bleximenib (a Menin-MLL inhibitor) to venetoclax (BCL2 inhibitor) plus azacitidine (DNA methylation inhibitor) improves outcomes compared to placebo with venetoclax and azacitidine in newly diagnosed AML patients harboring KMT2A rearrangements or NPM1 mutations who are ineligible for intensive chemotherapy.